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Cell survivalThe focus of this research was to investigate the role of protein kinase C-iota (PKC-ι) in regulation of Bad, a
pro-apoptotic BH3-only molecule of the Bcl-2 family in glioblastoma. Robust expression of PKC-ι is a hallmark
of human glioma and benign and malignant meningiomas. The results were obtained from the two human
glial tumor derived cell lines, T98G and U87MG. In these cells, PKC-ι co-localized and directly associated with
Bad, as shown by immunoﬂuorescence, immunoprecipitation, and Western blotting. Furthermore, in-vitro
kinase activity assay showed that PKC-ι directly phosphorylated Bad at phospho speciﬁc residues, Ser-112,
Ser-136 and Ser-155 which in turn induced inactivation of Bad and disruption of Bad/Bcl-XL dimer.
Knockdown of PKC-ι by siRNA exhibited a corresponding reduction in Bad phosphorylation suggesting that
PKC-ιmay be a Bad kinase. PKC-ι knockdown also induced apoptosis in both the cell lines. Since, PKC-ι is an
essential downstreammediator of the PI (3)-kinase, we hypothesize that glioma cell survival is mediated via a
PI (3)-kinase/PDK1/PKC-ι/Bad pathway. Treatment with PI (3)-kinase inhibitors Wortmannin and LY294002,
as well as PDK1 siRNA, inhibited PKC-ι activity and subsequent phosphorylation of Bad suggesting that PKC-ι
regulates the activity of Bad in a PI (3)-kinase dependent manner. Thus, our data suggest that glioma cell
survival occurs through a novel PI (3)-kinase/PDK1/PKC-ι/BAD mediated pathway.ospital, 13000 Bruce B. Downs
2000x6967; fax: +1 813 972
vedo-Duncan).
B.V.Published by Elsevier B.V.1. Introduction
Glioblastoma multiforme is the most lethal form of all primary
brain tumors with median survival time being less than a year. Rapid
development, aggressive proliferation and susceptibility to invasion
and metastasis cause poor prognosis in glioblastoma. Progress in
glioblastoma therapy has remained stagnant despite rigorous thera-
peutic methods such as surgery, radiation and chemotherapy [1,2].
Thus, there is a pressing need to identify novel molecular targets that
might help improve survival of glioblastoma patients.
Rapid glioma growth and survival have been attributed to inherently
high levels of protein kinase Cs (PKC) [3]. The PKC family is comprised of
twelve distinct isozymes classiﬁed on their requirement of speciﬁc
activators and co-factors [4–6]. PI (3)-kinase is frequently augmented in
glioblastoma due to activatingmutations or ampliﬁcations in epidermal
growth factor receptor (36% of the cases) or loss of function/deletion of
PTEN (25% of the cases) [7,8]. Over activation of PI (3)-kinase is involved
in glioblastoma cell proliferation and invasion [9,10]. The atypical PKC
family member, PKC-ι is a targeted mediator in the PI (3)-kinase signal
transduction repertoire [11]. PKC-ιwas of special interest as it has beenshown to be involved in tumor proliferation, angiogenesis, cell invasion
and cell survival aswell as induction of chemoresistance in several types
of cancers [12–17]. PI (3)-kinase induces activation of phosphoinosi-
tide-dependent kinase (PDK) 1 which in turn phosphorylates and
activates atypical PKCs [18]. Importance of PKC-ι as a signalingmediator
is attributed to the fact that it can function as an oncogene [19,20].
Bcl-2 (B cell lymphoma-2) family members are vital regulators of
the mitochondrial cell death machinery and are comprised of 15
members [21]. Bcl-2 and Bcl-XL promote cell survival whereas Bax,
Bak and several BH3 only proteins promote apoptosis [22,23]. Among
the BH3 only protein, Bad lacks the hydrophobic C-terminal domain
which prevents its direct mitochondrial interaction [24,25]. Bad
activity is dependent on three prime residues—Ser112, Ser136 and
Ser155 [26]. Upon external death signals, these residues remain
dephosphorylated which enables Bad to associate with Bcl-2/Bcl-XL
[27]. Survival kinases phosphorylate these residues deactivating and
disrupting Bad/Bcl-XL dimerization [28]. Dissociated Bad further
binds to 14-3-3 scaffold protein and is subsequently degraded [29].
Such imbalance among the Bcl-2 family of proteins with more
dependency on anti-apoptotic members is often observed to occur in
cancer cells [30,31].
We have previously reported that PKC-ι is highly expressed in
transformed phenotypes of human glioma and benign and malignant
meningioma [32]; however, little is understood about its role in glioma
cell survival. PKC-ι has been shown to inhibit the pro-apoptotic function
Fig. 1. Expression proﬁle of PKC-ι, Bad and Bcl-XL in T98G and U87MG cells. PKC-ι, Bad,
Bcl-XL and Caspase-3 expression levels in actively proliferating and contact inhibited
plus serum starved T98G and U87MG cells were determined by Western blot analysis.
β-actin indicates equal loading of the total lysate. Data is representative of N=3
independent experiments.
1191S. Desai et al. / Biochimica et Biophysica Acta 1813 (2011) 1190–1197of Bad in non-small cell lung cancer (NSCLC) cells when activated by
nitrosoamine 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK)
[33]. In this study we provide evidence that PKC-ι inhibited the pro-
apoptotic function of Bad to promote glioma cell survival. PI (3)-kinase
inhibition, PDK1 inhibition and knockdown of PKC-ι activity upon siRNA
treatment exhibited corresponding reduction in Bad phosphorylation
preventing glioma cell survival. Thus, our data suggest the presence of a
novel PI (3)-kinase/PDK1/PKC-ι/Bad signaling cascade. Targeting this
pathway may be a possible glioblastoma targeted therapy.
2. Materials and methods
2.1. Materials
Recombinant active PKC-ι, PKC-ζ andprimary antibodies for Bad and
PKC-ζ were purchased from Millipore (Temecula, CA). PKC-ι primary
antibody was purchased from BD Biosciences (San Jose, CA). Bad,
phospho-Bad Ser-112, phospho-Bad Ser-136, phospho-Bad Ser-155,
β-actin, and histone H1 primary antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Bcl-XL, 14-3-3, PDK1, Poly adipose
ribose polymerase (PARP), cysteine aspartic acid proteases (Caspase)-3,
cytochrome C and survivin primary antibodies were purchased from
Cell Signaling Technology (Danvers, MA). Horseradish peroxidase
(HRP) conjugated bovine anti-goat IgG and HRP goat anti-rabbit IgG,
as well as secondary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). HRP conjugated goat anti-mouse
Goat×Mouse IgG secondary antibody was purchased from Accurate
(Westbury, NY). Normal rabbit IgG was purchased from Upstate
(Upstate, NY). Wortmannin, LY294002 and anti-rabbit IgG (whole
molecule)-conjugated with agarose beads (1:1 v/v) were purchased
from Sigma-Aldrich (St. Louis,MO). PKC-ι silencing RNA (siRNA), PKC-ζ
siRNA and PDK1 siRNA were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). All the chemicals were purchased from Sigma-Aldrich,
Fisher Scientiﬁc (Norcross, GA), Pierce (Rockford, MO), Bio-Rad
(Richmond, CA), Invitrogen (Carlsbad, CA) unless otherwise stated.
2.2. Cell culture
T98G (CRL-1690) and U87MG (HTB-14) cells were obtained from
the American Tissue Culture Collection (Rockville, MD, USA). The T98G
cell linewas isolated as a spontaneous variant of the parental T98G cells
whichwerederived fromaglioblastomamultiforme tumorof a 61-year-
old Caucasian male. The cells have a hyperpentaploid chromosome
count and display immortality but are not tumorigenic in nude mice.
The doubling time for T98G cells is approximately 18 h. The trait that
distinguishes T98G cells from fully transformed cells is that they behave
similarly to normal cells and can become arrested and stationary in G1
phase [34]. The U87MG is classiﬁed as a grade IV astrocytoma and was
isolated from highly malignant glioblastoma of a 44-year-old Caucasian
female. The cells have a hypodiploid chromosome count and display
epithelial-like morphology and are tumorigenic in nude mice. The
doubling timeofU87MGcells is approximately 32 h. Both cell lineswere
cultured as a monolayer in 75 cm2 ﬂasks containing Eagles minimum
essential medium (MEM), 10% fetal bovine serum (FBS) and antibiotics
(penicillin 10 U/ml and streptomycin 10 μg/ml) at 37 °C in a humidiﬁed
atmosphere containing 5% CO2.
2.3. Cell-cycle time course and cell fractionation
T98G and U87MG cells were cultured as monolayers in 150 mm
tissue culture plates until 50–60% conﬂuent, followed by serum
starvation for 48 h. Subsequently, starvation media was removed and
complete media was added to each plate to allow cells to complete the
cell cycle (24 h for T98G and 36 h for U87MG). T98G cells were
harvested every 2 h and U87MG cells were harvested every 3 h by
placing the ﬂask on ice and washing twice with ice cold 1×. Cells weresubsequently scraped, re-suspended in 500 μl of homogenization buffer
(50 mM HEPES, pH 7.5), 150 mM sodium chloride, 0.5% Triton X-100,
1 mM EDTA (ethylenediaminetetraaecetic acid) and 2 mM EGTA
[glycol-bis(2-aminoethylether)-N, N, N′, N′-tetraacetic acid], 1 mM
orthovanadate, 0.5 M sodium ﬂuoride, 0.2 M PMSF (phenylmethylsul-
phonyl ﬂuoride), 1 mM DTT (dithiothreitol), and 0.15 U/ml aprotinin
[35]. Cell suspensions were subsequently sonicated and centrifuged at
16,000g. Protein content was measured according to Bradford [35].
2.4. Immunoprecipitation and Western blot analysis
Total protein (1 mg) was immunoprecipitated (IP) using anti-Bad or
anti-PKC-ιprimary antibody and subsequently subjected toWestern blot
analysis. Both protocols were followed according to Win H. et al. [36].
2.5. PKC activity assay
PKC activity assaywas performed by suspending recombinant active
PKC-ι, recombinant active PKC-ζ (0.5 μg each) individually in 200 μl of
PKC kinase buffer [37] to test the ability of each PKC to phosphorylate
recombinant aswell as endogenously immunoprecipitatedBad. ThePKC
kinase buffer consisted of 20 mM Tris–HCl (pH 7.5), 6 mMmagnesium
acetate, phosphotidylserine (5 μg) and adenosine triphosphate (ATP)
(0.96 μg). The reaction was terminated after incubation for 30 min at
30 °C by addition of sample loading buffer by placing the samples on ice.
Proteins were subsequently fractionated by SDS-PAGE and analyzed
using Western blot analysis.
2.6. Immunoﬂuorescence
Approximately 1×106 cells were plated and grown in 2-well culture
slides (Collagen type I coated). Twenty-four hours post-plating, cells
were washed with cold 1× DPBS and ﬁxed with 1:1 concentration of
methanol and acetone for 5 min at−20 °C. Cells were incubated with
8%normal goat serumblockingbuffer for 45 min followedby incubation
with anti-mouse antibody against PKC-ι for 90 min and subsequently
incubated with anti-mouse secondary antibody for 30 min followed by
staining with ﬂuorescein isothiocyanate (FITC) dye diluted in its
blocking buffer (Vector Laboratories, Burlingame, CA) for 30 min. Cells
were washed 3 times with 1× DPBS followed by blocking with 8%
normal horse serum for 45 min. Subsequently, cells were incubated
with primary anti-rabbit antibody against Bad for 90 min and then
incubated with anti-rabbit secondary antibody for 30 min followed by
stainingwith Texas red diluted in its blocking buffer. Cells werewashed
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medium containing DAPI (4′, 6-diamidino-2-phenylindole) staining
blue. Cells were observed with a Nikon Eclipse TE2000-U microscope.
Pictures were captured in NIS-Elements F Version 2.10. To illustrate
subcellular regions of protein co-localization, individual red and green-
stained images derived from the same ﬁeld were merged in Image-Pro
Express Version 5.1.Fig. 2. PKC-ι co-localizes and directly associates with Bad. (A, top panel) Displays IF contro
from FITC green used to detect PKC-ι and the ﬂuorescence from Texas Red to detect Bad. As r
depicts co-localization of PKC-ι and Bad in the cytosol. IF data represented are that of N=
cytoplasmic and nuclear fraction as explained in the “Materials and methods” section andW
expressed in the nuclear and cytoplasmic nuclear fraction of both cells, whereas Bad is expr
was used as the purity control for the nuclear fraction. (C–D) Whole cell extracts (1 mg) from
Proteins were separated by SDS-PAGE and were immunoblotted for PKC-ι and Bad. The ﬁrst n
1:1 v/v) and the second negative control (−) contains whole cell extract plus rabbit IgG who
with Bad in T98G cells in its 24 h cell cycle. (D) PKC-ι in U87MG cells associates with Bad at m
(36 h). Data represent N=3 independent experiments.2.7. Inhibition of gene expression
PKC-ι siRNA was a pool of three combined RNA sequences for
targeting PKC-ι. Their mRNA sequences were
663: 5′-CAAGCCAAGCGUUUCAACA-3′
5′-UGUUGAAACGCUUGGCUUG-3′ls incubated without primary antibody. (A, bottom panel) Represents the ﬂuorescence
eported by Jin et al. [33], the merged image of green and red ﬂuorescence (yellow color)
3 independent experiments. (B) Both T98G and U87MG cells were fractionated into
estern blot analysis was performed to determine the expression of the proteins. PKC-ι is
essed only in the cytoplasmic fraction. β-actin was used as loading control. Histone H1
each time point (every 2 h for T98G and 3 h for U87MG) were IP with PKC-ι antibody.
egative control (−) contains whole cell extract plus rabbit IgGwhole molecule (50 μl of
le molecule (50 μl) and normal rabbit IgG serum (5 μg). (C) PKC-ι transiently associates
ost time points compared to T98G though its expression varies throughout the cell cycle
Fig. 3. PKC-ι induces direct phosphorylation of Bad. The ﬁrst negative control (−) contains whole cell extract plus rabbit IgG whole molecule (50 μl of 1:1 v/v) and the second
negative control (−) contains whole cell extract plus rabbit IgG whole molecule (50 μl) and normal rabbit IgG serum (5 μg). (A) IP Bad, IP PKC-ι and co-IP from T98G and U87MG
cells were subjected to kinase activity assay. Phosphorylation of Bad at S112, S136, S155 and Pan Bad were quantiﬁed using Western blot analysis. (B) IP Bad from both T98G and
U87MG cells was incubated with active PKC-ι (0.5 μg) in an in-vitro kinase activity assay as explained in “Materials and methods.”Western blot analysis was performed to determine
phosphorylation of Bad at S112, S136 and S155 and Pan Bad. (C, upper panel) Recombinant Bad (3.0 μg) was incubated with puriﬁed, active PKC-ι and PKC-ζ (0.5 μg) for 30 min in an
in-vitro kinase assay. Western blot analysis was performed to determine pBad at S112, S136, S155 and Pan Bad. (C, lower panel) Recombinant MBP (3.0ug) was incubated with active
PKC-ι and PKC-ζ (0.5 μg) for 30 min in an in-vitro kinase assay followed by Western blot analysis to determine pMBP at T98. (D) Bad/Bcl-XL complex was IP from T98G and U87MG
cells and subsequently incubated with active PKC-ι (0.5 μg) for 30 min in an in-vitro kinase activity assay. The samples were centrifuged at 16,000g for 15 min. Western blot analysis
was performed on the resulting supernatant and the beads to determine the amount of bound Bcl-XL, unbound Bcl-XL and Pan Bad. (E) Bad/14-3-3 complex was IP from both the cell
lines and subsequently incubated with active PKC-ι (0.5 μg) for 30 min in an in-vitro kinase activity assay. The samples were centrifuged at 16,000g for 15 min. Western blot analysis
was performed on the resulting supernatant and the beads to determine the amount of bound 14-3-3, Pan Bad. Western blots are representative of three independent experiments.
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5′-AUGACAACCCAAUCGUUCC-3′
2137: 5′-CCCAAUAUCUUCUCUUGUA-3′
5′-UACAAGAGAAGAUAUUGGG-3′
and control siRNA contained a scrambled sequence which does not
lead to speciﬁc degradation of any known cellular mRNA and whose
sequence is a proprietary of Santa Cruz Biotechnology.
The experiments performed with siRNA are as follows:
Approximately, 4×103T98Gcellsweregrown in96well tissue culture
plates. Twenty-four hour post-plating, cells were exposed to a
increasing concentrations of either PKC-ι or control siRNA (25 nM–
125 nM) for 48 h. Cell proliferation was assessed using MTS assay.
Approximately, 1×106 cells were grown in 100 mm tissue culture
plates. Twenty-four hour post-plating, cells were treated with
either PKC-ι or control siRNA (100 nM). Cells were harvested
every 24 h and cell viability was quantiﬁed using trypan blue
exclusion assay. Western blot analysis with total protein (30 μg)
was performed to determine the expression of PKC-ι and PKC-ζ.
Total protein (30–100 μg) was also separated by Western blot
analysis to investigate the expression of several apoptotic markers
such as anti-whole PARP, anti-PARP cleavage, anti-Caspase 3, anti-
cytochrome C and anti-survivin antibodies.Approximately, 1×106 cells were grown asmonolayers in 100 mm
tissue culture plates. Twenty-four hour post-plating, cells were
treated with either PKC-ι or control siRNA (100 nM). Cells were
harvested after 24 h treatment and Bad was IP (1 mg) followed by
kinase activity assay and Western blot to investigate to amount of
Bad phosphorylation and Bcl-XL expression in both T98G and
U87MG cells. Another set of IP Bad was incubated with puriﬁed,
active PKC-ι in in-vitro kinase assay to examine the level of Bad
phosphorylation.
2.8. Trypan blue exclusion assay
The protocol for trypan blue exclusion assay was carried out as
explained under Win. H. et al. [36].2.9. (3-(4, 5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (MTS) assay
Approximately, 4×103 T98G cells were grown in 96 well tissue
culture plates. Twenty-four hours post-plating, cells were treated
with either PKC-ι or control siRNA (25 nM–125 nM) for 24–48 h. At
the speciﬁc time points, cells were incubated for 3 h withMTS reagent
according to manufacturer's instructions (Promega). Cell viability was
1194 S. Desai et al. / Biochimica et Biophysica Acta 1813 (2011) 1190–1197quantiﬁed by measuring the absorbance at 490 nm using a microtiter
plate reader.2.10. Subcellular fractionation
The protocol for subcellular fractionation (nuclear and cytoplasmic
extraction) was performed according toWin H. et al. [38]. Nuclear and
cytoplasmic extracts were subjected to Western blot analysis to
determine PKC-ι, Bad, β-actin and histone H1 expression.2.11. Densitometry
Intensity of each band was measured using the Quantity One, 1-D
analysis software (Bio-Rad Laboratories). In order to achieve the correct
intensity of each band, the background intensity was subtracted from the
intensity of each band. Mean absorbance of three independent studies
were compared by means of Student's t-test.3. Results
3.1. PKC-ι is over expressed in actively proliferating glioma cells
In 50% conﬂuent T98G cells (actively proliferating cells), there was
an increase in the expression of PKC-ι (90-fold, P=0.001) and Bcl-XL
(66-fold, P=0.006) when compared to 100% conﬂuent plus serum
starved cells (contact inhibited). Similarly, in U87MG cells, an increase
in the levels of PKC-ι (50-fold, P=0.008) and Bcl-XL (20-fold,
P=0.01) was observed in actively proliferating cells compared to
serum starved cells. In contrast, the expression of Bad was enhanced
in serum starved cells versus actively proliferating cells (44-fold in
T98G, P=0.004 and 52-fold in U87MG, P=0.002). Caspase-3
expression was equal in 50% conﬂuent and 100% serum starved cells
(Fig. 1). Caspase-3 expression levels were analyzed to ensure that the
decrease in the expression of PKC-ι was not an outcome of cells
undergoing apoptosis. β-actin was used as the loading control.Fig. 4. Effect of PI (3)-kinase inhibition and PDK1 knockdown in T98G and U87MG cells.
(A) Western blot analysis of T98G and U87MG cells for phospho-PKC-ι (T555), Pan
PKC-ι, phospho-Bad (S112), (S136), (S155) and Pan Bad after individual treatment for
2 h with LY294002 (50 μM) and Wortmannin (0.1 μM). (B) Both the cells were treated
with PDK1 siRNA (100 nM for 24 h) followed by Western blot analysis to detect
phospho-PKC-ι (T555), phospho-Bad (S112), (S136), (S155) and Pan PKC-ι and Bad.
Data are representative of three independent experiments.3.2. PKC-ι co-localizes and directly associates with Bad
CellulardistributionofBadandBcl-XL inT98Gcellswasdeterminedby
double immunoﬂuorescence (IF). Negative controls for FITC green, Texas
red and their merged image exhibited minimal background immunoﬂu-
orescence (IF) (Fig. 2A, top panel). PKC-ι had some nuclear staining but
was stronger in the cytoplasmic region (FITC green) whereas Bad stained
only in cytoplasmic fraction of the cells (Texas red) (Fig. 2A, bottom
panel). Merging of the two individual frames showed that PKC-ι
predominantly co-localized with Bad in the cytoplasmic region of the
cells as displayed by yellow coloration (Fig. 2A, bottom panel). Small
crescent shaped structures were observed near the perinuclear region of
the cells, as indicated by the arrows. The identity of this structure requires
further investigation. Subcellular fractionation of both T98G and U87MG
cells showed that PKC-ιwaspresent inboth cytoplasmic aswell asnuclear
fractions (Pb0.01 forT98GandU87MG),whereas, Badwaspresentonly in
the cytoplasmic fraction of the cells (P=0.002). β-actin was used as
loading control. Histone H1 was used as a purity control for nuclear
fraction (Fig. 2B).
To further demonstrate that PKC-ι directly associates with Bad,
PKC-ι was immunoprecipitated. In T98G cells, PKC-ι was constitu-
tively expressed at all time points and directly associated with Bad.
The association, however, was transient as observed at T0, T6, T14,
T16 hours (Fig. 2C). Although PKC-ι associated with Bad in U87MG
cells at most time points (T0–T36 h), distinct variation in the Bad
expression was observed (Fig. 2D). The reason for such expression
requires further investigation.3.3. PKC-ι directly phosphorylates Bad at all three serine residues in-
vitro
Since, our data showed that PKC-ι directly associates with Bad in
both T98G and U87MG cells (Fig. 2C, D), we examined whether PKC-ι
is a probable kinase to Bad in glioblastoma. Signiﬁcant increase in the
levels of pBad at S112, S136 and S155 in co-IP (PKC-ι and Bad)
samples compared to individual IP samples (Fig. 3A) suggest that Bad
might be a direct downstream substrate to PKC-ι in T98G and U87MG
cells. Further, when puriﬁed active PKC-ιwas incubatedwith IP Bad in
an in-vitro kinase assay, active PKC-ι directly phosphorylated Bad at
all three serine residues (Fig. 3B, Pb0.05 for all the residues). As
reported by Jin et al. [33], our data also showed that active PKC-ι
phosphorylated recombinant Bad at all three residues (Pb0.01 for all
residues) (Fig. 3C, upper panel). In contrast, when, another atypical
PKC, active PKC-ζ (70% homologous to PKC-ι) was incubated with
recombinant Bad in an in-vitro kinase assay, PKC-ζ phosphorylated
Bad at only S112 residue (P=0.02) (Fig. 3C, upper panel) suggesting
that it could also regulate Bad but would require other kinases in
order to completely abrogate the pro-apoptotic function of Bad. To
conﬁrm that the activity of PKC-ζ was not compromised, PKC-ι and
PKC-ζ were subjected to an in-vitro kinase activity assay using a
common substrate, myelin basic protein (MBP). Results showed that
both PKC-ι and PKC-ζ induced equivalent phosphorylation of MBP at
T98, demonstrating equal activity (Pb0.01) (Fig. 3C, bottom panel).
Furthermore, when Bad-associated Bcl-XL (bound Bcl-XL) was IP
and incubated with puriﬁed active PKC-ι (0.5 μg) in an in-vitro kinase
assay,we founddecrease in the amounts of boundBcl-XL and increase in
the levels of unbound Bcl-XL (Fig. 3D) in both T98G (P=0.013) and
U87MG cells (P=0.002). Additionally, when, Bad-associated 14-3-3
(bound14-3-3)was IP and incubatedwith puriﬁed active PKC-ι (0.5 μg)
in an in-vitro kinase assay, we found higher amounts of 14-3-3 in the
samples incubated with PKC-ι, suggesting that increased phosphoryla-
tion of Bad (Fig. 3B) as well as Bad/Bcl-XL dissociation (Fig. 3D) led to
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U87MG cells (P=0.023). These ﬁndings indicated that PKC-ι is a
potential upstream kinase to Bad.
3.4. Inhibition of PKC-ι activity leads to corresponding reduction in Bad
phosphorylation
Previous studies showed that pharmacological inhibition of PI (3)-
kinase blocked PKC-ι activity, suggesting that PI (3)-kinase is an
upstream regulator of PKC-ι in glioblastoma [9]. Similarly, our results
indicated that treatment of both T98G and U87MG cells with
LY294002 (50 μM) and Wortmannin (0.1 μM) for 2 h blocked PKC-ι
activity in the form of diminished phosphorylation at T555 residue
(53% with LY294002 and 68% with Wortmannin in T98G cells), (69%
with LY294002 and 83% with Wortmannin in U87MG cells). Marked
reduction in the amount of Bad phosphorylation at S112, S136 and
S155 was also observed (Fig. 4A).
PDK1 is a downstreammediator of PI (3)-kinase and previous studies
have shown that PDK1 interacts and regulates the activity of atypical PKCs
[18]. Thus, we investigated the effect of PDK1 knockdown on PKC-ι (70%
homologous to PKC-ζ) activity in glioma cells. Our data showed that
inhibition of PDK1 by siRNA (100 nM) inhibited the phosphorylation of
PKC-ι at T555. Subsequent reduction in the levels of Bad phosphorylation
at S112, S136 and S155 was also observed (Fig. 4B). Additionally, it has
also been shown that in embryonic stemcells, where PDK1is knockedout,
expression of atypical PKC isoforms (PKC-ζ, PRK1 and PRK2) wasFig. 5. PKC-ι is required for glioma cell proliferation and survival. (A) T98G cells were treated
for 24 and 48 h. At each time point, cell proliferation was detected using MTS assay. Data rep
with control siRNA or PKC-ι siRNA (100 nM) for 24–48 h. At the indicated time points,
independent studies. (C)Western blot analysis was performed to determine the expression o
three independent studies. (D) Control siRNA or PKC-ι siRNA (100 nM for 24 h) treated T98G
blot to detect PARP, PARP cleavage, Caspase-3, cytochrome C and survivin. β-Actin displayssigniﬁcantly reduced [39]. Thus, we investigated the expression levels of
PKC-ι in glioma cells that were treated with PDK1 siRNA. Results showed
marked reduction in expression of PKC-ι in PDK1 knockdown cells
suggesting that PDK1 could also regulate PKC-ι expression; however
further investigation may be required to explore this possibility.
3.5. PKC-ι siRNA potently depletes cell proliferation, cell viability and
promotes apoptosis
Treatment of T98G cells with PKC-ι siRNA (25 nM–125 nM) over a
48 h time course was performed using MTS assay. The data showed
that PKC-ι siRNA signiﬁcantly inhibited cell proliferation of T98G cells
with 71.4% at 24 h using a concentration of 100 nM (Pb0.001)
(Fig. 5A). This data conﬁrmed the effective dose treatment to be used
for further experiments. Trypan blue exclusion assay also showed that
PKC-ι siRNA (100 nM) signiﬁcantly inhibited cell viability of T98G
(74% at 24 h and 63% at 48 h) and U87MG (85% at 24 h and 72% at
48 h) cells (Fig. 5B).Western blot analysis illustrated that PKC-ι siRNA
treated cells showed diminished expression of PKC-ι in T98G (77% at
24 h and 61% at 48 h) and U87MG (80% at 24 h and 69% at 48 h) cells
compared to control siRNA treated cells (Fig. 5C). The silencing effect
of PKC-ιwas highly speciﬁc as no cross reactivity was observed when
the membrane was immunoblotted for PKC-ζ (70% homologous to
PKC-ι) (Fig. 5C). In addition, PKC-ι siRNA (100 nM) treated cells
displayed distinct morphological changes such as loss of cell
membrane symmetry and cell shrinkage as well as detachment ofwith increasing concentration of either control siRNA or PKC-ι siRNA (25 nM–125 nM)
resent N=3 independent studies. (B) Both T98G and U87MG cells were treated either
cell viability was quantiﬁed using trypan blue exclusion assay. Data represent three
f PKC-ι and PKC-ζ. β-Actin displays equal loading of protein.Western blots representing
and U87MG cells were harvested and total protein (100 μg) was analyzed by Western
equal protein loading. Data represent N=3 independent experiments.
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undergoing apoptosis. Several apoptotic markers such as Caspase-3
activation, PARP cleavage, release of cytochrome C as well as decrease
in expression of survivin were also observed (Fig. 5D).
3.6. PKC-ι knockdown diminished Bad phosphorylation, augmented Bad/
Bcl-XL association and inhibited Bad/14-3-3 dimerization
When T98G and U87MG cells were treated with PKC-ι siRNA
(100 nM for 24 h), Bad phosphorylation at S112, S136 and S155 was
signiﬁcantly inhibited in both the cell lines (Fig. 6A). Furthermore,
incubation with puriﬁed, active PKC-ι (0.5 μg) restored the amount of
Bad phosphorylation in PKC-ι siRNA treated cells (Fig. 6A). Also, Bad-
associated Bcl-XL (bound Bcl-Xl) increased (P=0.02) and Bad-
associated 14-3-3 decreased (P=0.004) in PKC-ι siRNA treated cells
(Fig. 6B). In addition, when T98G and U87MG cells were treated with
PKC-ζ siRNA, Bad phosphorylation at S112 (Pb0.05) was inhibited
while phosphorylation at S136 and S155 remained constitutive
(Fig. 6C). These results indicated that PKC-ζ does not have the ability
to completely inhibit Bad function.
4. Discussion
Glioblastoma multiforme is the most fatal of all brain tumors and
new targeted therapies are critically needed. Our data supports
previous ﬁndings that have acknowledged the role of recognize PKC-ιFig. 6. Knockdown of PKC-ι exhibited corresponding reduction in Bad phosphorylation
and led to increase in Bad/Bcl-XL interaction. (A) Both T98G and U87MG cells were
treated with either control siRNA or PKC-ι siRNA (100 nM) for 24 h. Subsequently, Bad
was IP and subjected to kinase activity assay followed byWestern blot to detect pBad at
S112, S136 and S155 and Pan Bad. Another set of IP Bad was incubated with puriﬁed,
active PKC-ι in an in-vitro kinase assay to detect its effect on the levels of pBad in PKC-ι
siRNA treated samples. (B) Bad was IP from both T98G and U87MG cells treated with
either control or PKC-ι siRNA. Bad-associated Bcl-XL (bound Bcl-XL), Bad-associated
14-3-3 (bound 14-3-3) and Pan Bad were analyzed using Bcl-XL, Pan 14-3-3 and Bad
antibodies respectively. (C) Both T98G and U87MG cells were treated with either
control siRNA or PKC-ζ siRNA (100 nM) for 24 h. Subsequently, Bad was IP and
subjected to kinase activity assay followed byWestern blot to detect pBad at S112, S136
and S155 and Pan Bad. Data are representative of three independent experiments.as a potential molecular target because it is involved in glioma cell
proliferation, invasion and metastasis [9,32]. In the current study, we
observed that PKC-ι also mediates cell survival in glioblastoma. In
order to elucidate the signaling mechanism by which PKC-ιmediates
its effect in glioblastoma, we investigated the role of the Bcl-2 family
proteins, Bad and Bcl-XL [40].
Ourpresent data showed an inverse relation between the expression
levels of PKC-ι and Bad in glioma cells, indicating a potential correlation
between these two proteins. In actively proliferating cells, PKC-ι is
highly expressed, complementing our previous ﬁndings [32], whereas
the levels of Bad were found to be diminished. However, under serum
starved conditions, where the cells were quiescent [32], the expression
of PKC-ι was signiﬁcantly decreased while that of Bad was higher.
Recent ﬁndings of Fernando et al. have shown that overexpression of
Bad in G1phase may not necessarily promote apoptosis, but it could
inhibit cell proliferation [41]. Additionally, Bad has been shown to arrest
G1-S progression of MCF7 breast cancer cells and this function depends
on the phosphorylation state of Bad. Thus, we hypothesized that, in
glioma cells, PKC-ι might be regulating the activity of Bad by
phosphorylation. In order to test our hypothesis, we analyzed the
association between PKC-ι and Bad in these cells. Since, we observed
transient association between PKC-ι and Bad, we speculated that there
could be a cell cycle dependent involvement of the two proteins. As
predicted, therewas transient but direct association of PKC-ι and Bad at
different time points in the cell cycle. Further investigation may be
required to comprehend the mechanism which induces such variable
Badexpression ingliomacells. Since, the functionof Bad is dictatedby its
three phosphorylation sites [27] and as PKC-ι directly associated with
Bad, we hypothesize that PKC-ιmight be an upstream kinase to Bad in
glioblastoma. Our results showed that endogenous PKC-ι not only co-
localized and associated with Bad but also directly phosphorylated Bad
at S112, S136 and S155. Additionally, puriﬁed, active PKC-ι induced in-
vitro phosphorylation of recombinant Bad, demonstrating that it is a
potential Bad kinase. This inactivation of Bad promoted its dissociation
from Bcl-XL and inhibited its ability to quench the survival function of
Bcl-XL. Furthermore, phosphorylated Bad dimerized with 14-3-3, a
known proteosomal scaffold protein.
PKC-ι knockdown reduced Bad phosphorylation, increased Bad/
Bcl-XL interaction and decreased Bad/14-3-3 dimerization. Further-
more, active PKC-ι re-stimulated the phosphorylation of Bad in these
cells conﬁrming that PKC-ι is a potent regulator of Bad function. Such
a cell survival mechanism has been previously shown in NSCLC;
however, the activation of PKC-ι in these cells was NNK dependent
[33]. In contrast, our results demonstrated that endogenous PKC-ι is
highly activated in glioblastoma and it promotes survival of cells
independent of any external stimulation.
PI (3)-kinase has been shown to induce activation of PDK1 which
subsequently phosphorylates and activates PKC-ι [9,11,18]. PI (3)-
kinase and PDK1 inhibition not only blocked PKC-ι activity but also
inhibited Bad phosphorylation. This suggests that glioma cell survival
occurs through a PI (3)-kinase signaling pathway. Intriguingly, PDK1
knockdown also signiﬁcantly inhibited the endogenous expression of
PKC-ι in our cells. Previous studies have shown that in embryonic
stem cells, where PDK1 was knocked out, there was a marked
reduction in the expression of atypical PKC isoforms (PKC-ζ, PRK1 and
PRK2) [39]; however, regulation of PKC-ι expression by PDK1 has
never been shown before. The mechanism by which PDK1 regulates
PKC-ι expression will require further investigation.
Ourdata also showed that knockdownof PKC-ι byPKC-ι siRNA led to
corresponding decrease in cell proliferation and initiation of apoptosis
in cells grown in tissue culture which is consistent with the ﬁnding of
Baldwin et al. [10]. These mechanisms contrast with those of other
cancers where such an effect was observed only in anchorage
independent cells signifying a tissue speciﬁc role of PKC-ι [12,42].
Collectively, our data suggest that PKC-ι promotes glioblastoma
cell survival by regulating the pro-apoptotic function of Bad through
1197S. Desai et al. / Biochimica et Biophysica Acta 1813 (2011) 1190–1197PI (3)-kinase in absence of any external stimulation. Thus, we show
that PKC-ι expression may be used as a prognostic marker for the
identiﬁcation of glioblastoma patients that may beneﬁt from anti-
PKC-ι therapy for personalized medicine.
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